The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Brian I. Rini

The Cleveland Clinic Taussig Cancer Center

Cleveland

Ohio

[email]@ccf.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio. 2012
  • Cleveland Clinic Taussig Cancer Institute, Main Campus, Euclid Avenue, Cleveland, USA. 2011
  • Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave/Desk R35, Cleveland. 2005 - 2011
  • Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. 2005 - 2009
  • University of California-San Francisco Comprehensive Cancer Center, San Francisco, California, USA. 2006

References

  1. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney : A randomized, double-blind, placebo-controlled, phase 2 study. Rini, B., Szczylik, C., Tannir, N.M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L.Y., Fishman, M., Ramlau, R., Ravaud, A., Rogowski, W., Kracht, K., Sun, Y.N., Bass, M.B., Puhlmann, M., Escudier, B. Cancer (2012) [Pubmed]
  2. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Rini, B.I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T.E., Michaelson, M.D., Gorbunova, V.A., Gore, M.E., Rusakov, I.G., Negrier, S., Ou, Y.C., Castellano, D., Lim, H.Y., Uemura, H., Tarazi, J., Cella, D., Chen, C., Rosbrook, B., Kim, S., Motzer, R.J. Lancet (2011) [Pubmed]
  3. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. Rini, B.I., Cohen, D.P., Lu, D.R., Chen, I., Hariharan, S., Gore, M.E., Figlin, R.A., Baum, M.S., Motzer, R.J. J. Natl. Cancer Inst. (2011) [Pubmed]
  4. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Rini, B.I., Stein, M., Shannon, P., Eddy, S., Tyler, A., Stephenson, J.J., Catlett, L., Huang, B., Healey, D., Gordon, M. Cancer (2011) [Pubmed]
  5. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Rini, B.I. Clin. Cancer Res. (2010) [Pubmed]
  6. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Archer, L., Atkins, J.N., Picus, J., Czaykowski, P., Dutcher, J., Small, E.J. J. Clin. Oncol. (2010) [Pubmed]
  7. Resistance to targeted therapy in renal-cell carcinoma. Rini, B.I., Atkins, M.B. Lancet Oncol. (2009) [Pubmed]
  8. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Rini, B.I., Garcia, J.A., Cooney, M.M., Elson, P., Tyler, A., Beatty, K., Bokar, J., Mekhail, T., Bukowski, R.M., Budd, G.T., Triozzi, P., Borden, E., Ivy, P., Chen, H.X., Dolwati, A., Dreicer, R. Clin. Cancer Res. (2009) [Pubmed]
  9. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Rini, B.I. Cancer (2009) [Pubmed]
  10. Metastatic renal cell carcinoma: many treatment options, one patient. Rini, B.I. J. Clin. Oncol. (2009) [Pubmed]
  11. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Rini, B.I., Wilding, G., Hudes, G., Stadler, W.M., Kim, S., Tarazi, J., Rosbrook, B., Trask, P.C., Wood, L., Dutcher, J.P. J. Clin. Oncol. (2009) [Pubmed]
  12. Circulating tumor cells in metastatic castration-resistant prostate cancer. Rini, B.I. Curr. Oncol. Rep (2009) [Pubmed]
  13. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Rini, B.I., Flaherty, K. Urol. Oncol. (2008) [Pubmed]
  14. Temsirolimus, an inhibitor of mammalian target of rapamycin. Rini, B.I. Clin. Cancer Res. (2008) [Pubmed]
  15. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Ou, S.S., Archer, L., Atkins, J.N., Picus, J., Czaykowski, P., Dutcher, J., Small, E.J. J. Clin. Oncol. (2008) [Pubmed]
  16. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. Rini, B.I., Michaelson, M.D., Rosenberg, J.E., Bukowski, R.M., Sosman, J.A., Stadler, W.M., Hutson, T.E., Margolin, K., Harmon, C.S., DePrimo, S.E., Kim, S.T., Chen, I., George, D.J. J. Clin. Oncol. (2008) [Pubmed]
  17. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? Rini, B.I., Bukowski, R.M. Oncology (Williston Park, N.Y.) (2008) [Pubmed]
  18. Lapatinib therapy for patients with advanced renal cell carcinoma. Rini, B.I. Nat. Clin. Pract. Oncol (2008) [Pubmed]
  19. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Rini, B.I., Choueiri, T.K., Elson, P., Khasawneh, M.K., Cotta, C., Unnithan, J., Wood, L., Mekhail, T., Garcia, J., Dreicer, R., Bukowski, R.M. Cancer (2008) [Pubmed]
  20. Is sorafenib plus interferon alpha 2b safe and effective in patients with renal cell carcinoma? Rini, B.I. Nat. Clin. Pract. Urol (2008) [Pubmed]
  21. Sunitinib. Rini, B.I. Expert. Opin. Pharmacother (2007) [Pubmed]
  22. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Rini, B.I. Clin. Cancer Res. (2007) [Pubmed]
  23. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Rini, B.I., Tamaskar, I., Shaheen, P., Salas, R., Garcia, J., Wood, L., Reddy, S., Dreicer, R., Bukowski, R.M. J. Natl. Cancer Inst. (2007) [Pubmed]
  24. What is standard initial systemic therapy in metastatic renal cell carcinoma?. Rini, B.I., McDermott, D., Atkins, M. Clinical. Genitourinary. Cancer (2007) [Pubmed]
  25. Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib. Rini, B.I. Nat. Clin. Pract. Oncol (2006) [Pubmed]
  26. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Rini, B.I., Weinberg, V., Dunlap, S., Elchinoff, A., Yu, N., Bok, R., Simko, J., Small, E.J. Cancer (2006) [Pubmed]
  27. Sorafenib. Rini, B.I. Expert. Opin. Pharmacother (2006) [Pubmed]
  28. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Rini, B.I. Curr. Oncol. Rep (2006) [Pubmed]
  29. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. Rini, B.I., Fong, L., Weinberg, V., Kavanaugh, B., Small, E.J. J. Urol. (2006) [Pubmed]
  30. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Rini, B.I., Weinberg, V., Fong, L., Conry, S., Hershberg, R.M., Small, E.J. Cancer (2006) [Pubmed]
  31. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Rini, B.I., Halabi, S., Barrier, R., Margolin, K.A., Avigan, D., Logan, T., Stadler, W.M., McCarthy, P.L., Linker, C.A., Small, E.J. Biol. Blood Marrow Transplant. (2006) [Pubmed]
  32. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. Rini, B.I., Jaeger, E., Weinberg, V., Sein, N., Chew, K., Fong, K., Simko, J., Small, E.J., Waldman, F.M. BJU Int. (2006) [Pubmed]
  33. Current status and future directions of molecular markers in renal cell carcinoma. Rini, B.I. Curr. Opin. Urol (2006) [Pubmed]
  34. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?. Rini, B.I. Expert. Rev. Anticancer. Ther (2006) [Pubmed]
  35. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Rini, B.I., Shaw, V., Rosenberg, J.E., Kim, S.T., Chen, I. Clinical. Genitourinary. Cancer (2006) [Pubmed]
  36. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. Rini, B.I., Sosman, J.A., Motzer, R.J. BJU Int. (2005) [Pubmed]
  37. SU11248 and AG013736: current data and future trials in renal cell carcinoma. Rini, B.I. Clinical. Genitourinary. Cancer (2005) [Pubmed]
 
WikiGenes - Universities